BIOFILCHEM2024-01-012024-03-31 BIOFILCHEM2024-01-012024-03-31 BIOFILCHEM2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member BIOFILCHEM2024-03-31 BIOFILCHEM2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue01Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue02Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue01Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue02Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults01Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults02Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults01Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults02Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets01Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets02Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member BIOFILCHEM2024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member BIOFILCHEM2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member BIOFILCHEM2024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524396 BIOFILCHEM NOTLISTED Biofil Chemicals & Pharmaceuticals Limited Equity 2023-04-01 2024-03-31 2024-05-30 2024-05-22 INR Lakhs Yearly 16:30:00 18:30:00 2024-05-30 2024-05-30 true Cash Flow Indirect Declaration of unmodified opinion Multi segment 2024-01-01 2024-03-31 Audited Standalone 152027000.00 4057000.00 156084000.00 -106802000.00 243609000.00 10530000.00 1986000.00 209000.00 774000.00 3030000.00 153336000.00 2748000.00 0.00 2748000.00 1100000.00 -839000.00 261000.00 0.00 2487000.00 0.00 0.00 0.00 0.00 2487000.00 1921000.00 4408000.00 0.00 0.00 162738000.00 10 0.15 0.15 0.00 0.00 0.15 0.15 1 The above Audited Financial Results for the Quarter and financial year ended March 31, 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on 30th May 2024. The above results have been audited by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs. 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. 3 The figures for the quarter ended 31st March 2024 and 31st March 2023 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter. 4 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments a. Pharma Division b. Chemicals Division . 5 Statutory Auditors of the Company has carried out audit of the books of accounts for the financial year 2023-2024 and issued us an Audit Report with unmodified opinion on Audited Financial Year for the quarter/year ended on 31st March, 2024, therefore the Company is not required to give statement of impact of Audit Qualification for Audit Report with modified opinion. 6 The aforesaid audited financial Results will be uploaded on the Company’s website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors. 7 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary. 8 The Statement of Assets & Liabilities as at March 31, 2024 is annexed with the results along with the Statement of Cash Flow. Multi segment 2023-04-01 2024-03-31 Audited Standalone 400353000.00 4897000.00 405250000.00 52574000.00 325226000.00 -2725000.00 6704000.00 415000.00 3994000.00 10408000.00 396596000.00 8654000.00 0.00 8654000.00 2400000.00 -839000.00 1561000.00 0.00 7093000.00 0.00 0.00 0.00 0.00 7093000.00 1921000.00 9014000.00 0.00 0.00 162738000.00 10 -18330000.00 0.44 0.44 0.00 0.00 0.44 0.44 Other Expenses 3030000.00 Other Expenses 10408000.00 86243000.00 0.00 0.00 0.00 0.00 0.00 509000.00 86752000.00 25497000.00 0.00 330291000.00 926000.00 21909000.00 0.00 353126000.00 5452000.00 384075000.00 470827000.00 162738000.00 19290000.00 182028000.00 182028000.00 0.00 0.00 0.00 3554000.00 3554000.00 4389000.00 275549000.00 279938000.00 2907000.00 2400000.00 285245000.00 288799000.00 470827000.00 Chemical Division 520000.00 Pharma Division 151507000.00 Chemical Division 121674000.00 Pharma Division 278679000.00 152027000.00 400353000.00 152027000.00 400353000.00 Chemical Division 569000.00 Pharma Division 2314000.00 Chemical Division 8856000.00 Pharma Division 107000.00 2883000.00 8963000.00 135000.00 310000.00 2748000.00 8653000.00 Chemical Division 236033000.00 Pharma Division 234794000.00 470827000.00 Chemical Division 91130000.00 Pharma Division 197669000.00 288799000.00 415000.00 -13363000.00 -125264000.00 0.00 551000.00 0.00 0.00 0.00 0.00 149050000.00 0.00 -133000.00 0.00 3994000.00 0.00 0.00 0.00 0.00 -326000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1921000.00 0.00 16845000.00 25499000.00 0.00 0.00 0.00 2400000.00 839000.00 23938000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 229000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -229000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 834000.00 0.00 0.00 0.00 415000.00 0.00 0.00 -1249000.00 22460000.00 0.00 22460000.00 376000.00 22836000.00 2567000.00 2567000.00 646000.00 646000.00 0.00 0.00